Figure 2.
![Categorical response analyses. Categorical responses to ibrutinib plus rituximab (I+R) and ibrutinib monotherapy (I) in the entire cohort (I, 118; I+R, 58) (A); patients with CXCR4 mutations (I, 44; I+R, 26), showing numerical improvements in VGPR (B); and patients with high IPSSWM scores (I, 46; I+R, 22) (C). Categorical responses according to CXCR4 mutational status in the entire cohort (WT, 104; mutated [MUT], 70) (D); in patients treated with I+R (WT, 32; MUT, 26) (E); and in patients treated with I alone (WT, 72; MUT, 44) (F). mR, minor response; NR, no response; PR, partial response.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/9/18/10.1182_bloodadvances.2025016536/1/blooda_adv-2025-016536-gr2.jpeg?Expires=1761632963&Signature=xLZkBoz2eMk~6jjVgfyvjbzePizM22IecKEy051cRJ2sPMWM9EhZ6Kq3XIsO8oyR3qmPrr2aeMfxZKF7z1aPnDqCocAzM5mZnIET3nOSNN04fcUWu4tgdigjX36k5unF86d6TVMrB01G08YIuaasp-U6KiGRYVMzRbaQ8M6aRVnunUFslUf4sN5EkAO8FiY070h~RWkTunM1gT1pgi5TUOkDyyYpXEFkCInwDXoHdaMoO~lpvPLRrsKZonPk0i0u2gd9-lbFQhyAcTON~3h0c5AjoN05TjIHrp635GGQllje3VSeq2KY3SAKDSw6KaxswTDCGgLWKvwuLzDj1iRYHQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Categorical response analyses. Categorical responses to ibrutinib plus rituximab (I+R) and ibrutinib monotherapy (I) in the entire cohort (I, 118; I+R, 58) (A); patients with CXCR4 mutations (I, 44; I+R, 26), showing numerical improvements in VGPR (B); and patients with high IPSSWM scores (I, 46; I+R, 22) (C). Categorical responses according to CXCR4 mutational status in the entire cohort (WT, 104; mutated [MUT], 70) (D); in patients treated with I+R (WT, 32; MUT, 26) (E); and in patients treated with I alone (WT, 72; MUT, 44) (F). mR, minor response; NR, no response; PR, partial response.
